L’elenco che segue contiene sia gli studi relativi alla sindrome post finasteride ma anche parte della bibliografia scientifica relativa agli effetti avversi/biologici degli inibitori della 5-alfa-reduttasi quali finasteride, dutasteride e Serenoa repens (Saw Palmetto). 

  1. Stachelek, J., Zwaans, B. M. M., Shtein, R., & Peters, K. M. (2025). Insights into the peripheral nature of persistent sexual dysfunction associated with post-finasteride, post-SSRI and post-accutane syndromes: lessons learned from a case study. International urology and nephrology, 10.1007/s11255-025-04373-w. Advance online publication. https://doi.org/10.1007/s11255-025-04373-w
  2. Carson, C. C. (2024). Post‐finasteride syndrome: real or myth? Trends in Urology & Men’s Health, 15(4), 22–24. Portico. https://doi.org/10.1002/tre.972
  3. Cho, H., Sung, S.-E., Jang, G., Esterhuizen, M., Ryu, C. S., Kim, Y., & Kim, Y. J. (2024). Adverse effects of the 5-alpha-reductase inhibitor finasteride on Daphnia magna: Endocrine system and lipid metabolism disruption. Ecotoxicology and Environmental Safety, 281, 116606. https://doi.org/10.1016/j.ecoenv.2024.116606
  4. Giatti, S., Cioffi, L., Diviccaro, S., Piazza, R., & Melcangi, R. C. (2024). Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level. Journal of Endocrinological Investigation, 47(10), 2565–2574. https://doi.org/10.1007/s40618-024-02345-y
  5. Giatti, S., Diviccaro, S., Cioffi, L., & Cosimo Melcangi, R. (2024). Post-Finasteride Syndrome And Post-Ssri Sexual Dysfunction: Two Clinical Conditions Apparently Distant, But Very Close. Frontiers in Neuroendocrinology, 72, 101114. https://doi.org/10.1016/j.yfrne.2023.101114
  6. Lonergan, E. M., Maher, S. M., Yaseen, I., & O’Shea, D. B. (2024). 8679 Case: The Sexual, Physical and Psychological Effects of Post-Finasteride Syndrome. Journal of the Endocrine Society, 8(Supplement_1). https://doi.org/10.1210/jendso/bvae163.1570
  7. Perelman, M. A. (2024). Comment on “The post-finasteride syndrome: possible etiological mechanisms and symptoms.” International Journal of Impotence Research. https://doi.org/10.1038/s41443-024-00886-7
  8. Zhong, X., Yang, Y., Wei, S., & Liu, Y. (2024). Multidimensional assessment of adverse events of finasteride: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024. https://doi.org/10.1101/2024.08.21.24312383
  9. Cho, Y., Bea, S., Bae, J.-H., Kim, D. H., Lee, J. H., & Shin, J.-Y. (2023). Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database. Expert Opinion on Drug Safety, 23(8), 1027–1033. https://doi.org/10.1080/14740338.2023.2294926
  10. Crescioli, G., Maggini, V., Raschi, E., Gonella, L. A., Luxi, N., Ippoliti, I., Di Giovanni, V., Bonaiuti, R., Firenzuoli, N., Gallo, E., Menniti‐Ippolito, F., Moretti, U., Trifirò, G., Vannacci, A., Firenzuoli, F., & Lombardi, N. (2023). Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports. Phytotherapy Research, 37(11), 5289–5299. Portico. https://doi.org/10.1002/ptr.7960
  11. Da Silva, M. H. A., Costa, W. S., Sampaio, F. J. B., & Souza, D. B. de. (2023). Effects of dutasteride and tamsulosin on penile morphology in a rodent model. International Braz j Urol, 49(3), 320–333. https://doi.org/10.1590/s1677-5538.ibju.2022.0583
  12. Diviccaro, S., Herian, M., Cioffi, L., Audano, M., Mitro, N., Caruso, D., Giatti, S., & Melcangi, R. C. (2023). Exploring rat corpus cavernosum alterations induced by finasteride treatment and withdrawal. Andrology, 12(3), 674–681. Portico. https://doi.org/10.1111/andr.13515
  13. Gül, M., Fode, M., Urkmez, A., Capogrosso, P., Falcone, M., Sarikaya, S., Sokolakis, I., Morgado, A., Morozov, A., Albersen, M., Russo, G. I., & Serefoglu, E. C. (2023). A clinical guide to rare male sexual disorders. Nature Reviews Urology, 21(1), 35–49. https://doi.org/10.1038/s41585-023-00803-5
  14. Laanani, M., Weill, A., Jollant, F., Zureik, M., & Dray-Spira, R. (2023). Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-32356-3
  15. Leliefeld, H. H. J., Debruyne, F. M. J., & Reisman, Y. (2023). The post-finasteride syndrome: possible etiological mechanisms and symptoms. International Journal of Impotence Research. https://doi.org/10.1038/s41443-023-00759-5
  16. Diviccaro, S., Giatti, S., Cioffi, L., Falvo, E., Herian, M., Caruso, D., & Melcangi, R. C. (2022). Gut Inflammation Induced by Finasteride Withdrawal: Therapeutic Effect of Allopregnanolone in Adult Male Rats. Biomolecules, 12(11), 1567. https://doi.org/10.3390/biom12111567
  17. Fierro, M. C., Yafi, F. A., & Reisman, Y. (2022). Post-Finasteride Syndrome. Textbook of Rare Sexual Medicine Conditions, 65–79. https://doi.org/10.1007/978-3-030-98263-8_6
  18. Asanad, K., Sholklapper, T., Samplaski, M. K., & Cacciamani, G. E. (2022). Global online interest in finasteride sexual side effects. International Journal of Impotence Research, 36(4), 408–413. https://doi.org/10.1038/s41443-022-00612-1
  19. Garcia-Argibay, M., Hiyoshi, A., Fall, K., & Montgomery, S. (2022). Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide. JAMA Network Open, 5(12), e2248135. https://doi.org/10.1001/jamanetworkopen.2022.48135
  20. Healy, D., Bahrick, A., Bak, M., Barbato, A., Calabrò, R. S., Chubak, B. M., Cosci, F., Csoka, A. B., D’Avanzo, B., Diviccaro, S., Giatti, S., Goldstein, I., Graf, H., Hellstrom, W. J. G., Irwig, M. S., Jannini, E. A., Janssen, P. K. C., Khera, M., Kumar, M. T., … Waraich, A. (2022). Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine, 33(1), 65–76. https://doi.org/10.3233/jrs-210023
  21. Li, X., Guo, Y., Lu, Y., Li, H., Yan, S., Li, H., & Li, Y. (2022). Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. Translational Andrology and Urology, 11(10), 1452–1457. https://doi.org/10.21037/tau-22-92
  22. Nguyen, D., Herzog, P., Cone, E., Labban, M., Zorn, K., Chughtai, B., Basaria, S., Elterman, D., Trinh, Q., & Bhojani, N. (2022). 222 Pharmacovigilance Analysis of Reports of Sexual Dysfunction Associated with Finasteride Use: Implications for the Post-Finasteride Syndrome. The Journal of Sexual Medicine, 19(Supplement_1), S112–S112. https://doi.org/10.1016/j.jsxm.2022.01.236
  23. Romero Pérez, P. (2022). Post-finasteride syndrome. Literature review. Arch.  Esp.  Urol. (Ed.  Impr. ), 382–399. https://pesquisa.bvsalud.org/portal/resource/pt/ibc-209222
  24. Ahire, A., Nair, K. P., Shankaranarayana Rao, B. S., & Srikumar, B. N. (2021). The potential involvement of cholinergic system in finasteride induced cognitive dysfunction. Psychoneuroendocrinology, 124, 105066. https://doi.org/10.1016/j.psyneuen.2020.105066
  25. Diviccaro, S., Cioffi, L., Falvo, E., Giatti, S., & Melcangi, R. C. (2021). Allopregnanolone: An overview on its synthesis and effects. Journal of Neuroendocrinology, 34(2). Portico. https://doi.org/10.1111/jne.12996
  26. Favilla, V., Cannarella, R., Trovato, F., Li Volti, G., Distefano, A., Grimaldi, E., La Camera, G., La Vignera, S., Condorelli, R. A., Calogero, A. E., & Cimino, S. (2021). Effects of dutasteride on sex hormones and cerebrospinal steroids in patients treated for benign prostatic hyperplasia. Endocrine, 73(3), 712–718. https://doi.org/10.1007/s12020-021-02675-4
  27. Gallo, E., Maggini, V., Lombardi, N., Crescioli, G., Sivelli, F., Vannacci, A., & Firenzuoli, F. (2021). Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance. British Journal of Clinical Pharmacology, 88(5), 2441–2443. Portico. https://doi.org/10.1111/bcp.15129
  28. Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2021). Finasteride for hair loss: a review. Journal of Dermatological Treatment, 33(4), 1938–1946. https://doi.org/10.1080/09546634.2021.1959506
  29. Howell, S., Song, W., Pastuszak, A., & Khera, M. (2021). Differential Gene Expression in Post-Fihttps://doi.org/10.1080/09546634.2021.1959506nasteride Syndrome Patients. The Journal of Sexual Medicine, 18(9), 1479–1490. https://doi.org/10.1016/j.jsxm.2021.05.009
  30. Borgo, F., Macandog, A. D., Diviccaro, S., Falvo, E., Giatti, S., Cavaletti, G., & Melcangi, R. C. (2020). Alterations of gut microbiota composition in post-finasteride patients: a pilot study. Journal of Endocrinological Investigation, 44(6), 1263–1273. https://doi.org/10.1007/s40618-020-01424-0
  31. Diviccaro, S., Melcangi, R. C., & Giatti, S. (2020). Post-finasteride syndrome: An emerging clinical problem. Neurobiology of Stress, 12, 100209. https://doi.org/10.1016/j.ynstr.2019.100209
  32. Khera, M., Than, J. K., Anaissie, J., Antar, A., Song, W., Losso, B., Pastuszak, A., Kohn, T., & Mirabal, J. R. (2020). Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. Translational Andrology and Urology, 9(3), 1201–1209. https://doi.org/10.21037/tau.2020.03.21
  33. Pereira, A. F. J. R., & Coelho, T. O. de A. (2020). Post-finasteride syndrome. Anais Brasileiros de Dermatologia, 95(3), 271–277. https://doi.org/10.1016/j.abd.2020.02.001
  34. Traish, A. M. (2020). Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm. The World Journal of Men’s Health, 38(3), 323. https://doi.org/10.5534/wjmh.200012
  35. Traish, A. M. (2020). Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and Sterility, 113(1), 21–50. https://doi.org/10.1016/j.fertnstert.2019.11.030
  36. Coskuner, E. R., Ozkan, B., & Culha, M. G. (2019). Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sexual Medicine Reviews, 7(2), 277–282. https://doi.org/10.1016/j.sxmr.2018.07.003
  37. Diviccaro, S., Giatti, S., Borgo, F., Barcella, M., Borghi, E., Trejo, J. L., Garcia-Segura, L. M., & Melcangi, R. C. (2019). Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology, 99, 206–215. https://doi.org/10.1016/j.psyneuen.2018.09.021
  38. Gray, S. L., & Semla, T. P. (2019). Post-finasteride syndrome. BMJ, l5047. https://doi.org/10.1136/bmj.l5047
  39. Maksym, R. B., Kajdy, A., & Rabijewski, M. (2019). Post-finasteride syndrome – does it really exist? The Aging Male, 22(4), 250–259. https://doi.org/10.1080/13685538.2018.1548589
  40. Melcangi, R. C., Casarini, L., Marino, M., Santi, D., Sperduti, S., Giatti, S., Diviccaro, S., Grimoldi, M., Caruso, D., Cavaletti, G., & Simoni, M. (2019). Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. Endocrine Connections, 8(8), 1118–1125. https://doi.org/10.1530/ec-19-0199
  41. Sasibhushana, R. B., Shankaranarayana Rao, B. S., & Srikumar, B. N. (2019). Repeated finasteride administration induces depression-like behavior in adult male rats. Behavioural Brain Research, 365, 185–189. https://doi.org/10.1016/j.bbr.2019.03.006
  42. Baas, W. R., Butcher, M. J., Lwin, A., Holland, B., Herberts, M., Clemons, J., Delfino, K., Althof, S., Kohler, T. S., & McVary, K. T. (2018). A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome. Urology, 120, 143–149. https://doi.org/10.1016/j.urology.2018.06.022
  43. Giatti, S., Diviccaro, S., Panzica, G., & Melcangi, R. C. (2018). Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine, 61(2), 180–193. https://doi.org/10.1007/s12020-018-1593-5
  44. Mervis, J. S., Borda, L. J., & Miteva, M. (2018). ‘Post-finasteride syndrome’: what to tell our female patients? British Journal of Dermatology, 179(3), 785–786. Portico. https://doi.org/10.1111/bjd.16658
  45. Trueb, R., Rezende, H., & Dias, M. R. G. (2018). A comment on the post-finasteride syndrome. International Journal of Trichology, 10(6), 255. https://doi.org/10.4103/ijt.ijt_61_18
  46. Seftel, A. D. (2018). Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome. Journal of Urology, 200(6), 1147–1148. https://doi.org/10.1016/j.juro.2018.08.078
  47. Than, J. K., Rodriguez, K., & Khera, M. (2018). Post-finasteride Syndrome: A Review of Current Literature. Current Sexual Health Reports, 10(3), 152–157. https://doi.org/10.1007/s11930-018-0163-4
  48. Traish, A. M. (2018). The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Current Sexual Health Reports, 10(3), 88–103. https://doi.org/10.1007/s11930-018-0161-6
  49. Walf, A. A., Kaurejo, S., & Frye, C. A. (2018). Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men. American Journal of Men’s Health, 12(4), 900–906. https://doi.org/10.1177/1557988317750989
  50. Corona, G., Tirabassi, G., Santi, D., Maseroli, E., Gacci, M., Dicuio, M., Sforza, A., Mannucci, E., & Maggi, M. (2017). Sexual dysfunction in subjects treated with inhibitors of 5α‐reductase for benign prostatic hyperplasia: a comprehensive review and meta‐analysis. Andrology, 5(4), 671–678. Portico. https://doi.org/10.1111/andr.12353
  51. Melcangi, R. C., Santi, D., Spezzano, R., Grimoldi, M., Tabacchi, T., Fusco, M. L., Diviccaro, S., Giatti, S., Carrà, G., Caruso, D., Simoni, M., & Cavaletti, G. (2017). Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. The Journal of Steroid Biochemistry and Molecular Biology, 171, 229–235. https://doi.org/10.1016/j.jsbmb.2017.04.003
  52. Motofei, I. G., Rowland, D. L., Georgescu, S. R., Tampa, M., Paunica, S., Constantin, V. D., Balalau, C., Manea, M., Baleanu, B. C., & Sinescu, I. (2017). Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo. Skin Pharmacology and Physiology, 30(1), 42–45. Portico. https://doi.org/10.1159/000455972
  53. Butcher, M., Baas, W., Lwin, A., Holland, B., Herberts, M., Clemons, J., Delfino, K., Althof, S. E., Kohler, T. S., & McVary, K. T. (2016). MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED? Journal of Urology, 195(4S). https://doi.org/10.1016/j.juro.2016.02.2469
  54. Fertig, R., Shapiro, J., Bergfeld, W., & Tosti, A. (2016). Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome. Skin Appendage Disorders, 2(3–4), 120–129. Portico. https://doi.org/10.1159/000450617
  55. Ganzer, C. A., & Jacobs, A. R. (2016). Emotional Consequences of Finasteride: Fool’s Gold. American Journal of Men’s Health, 12(1), 90–95. https://doi.org/10.1177/1557988316631624
  56. Sharma, N., Gupta, A., & Shukla, P. (2016). Atypical post-finasteride syndrome: A pharmacological riddle. Indian Journal of Pharmacology, 48(3), 316. https://doi.org/10.4103/0253-7613.182898
  57. Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. The Journal of clinical and aesthetic dermatology, 9(7), 56–62. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023004/
  58. Hyun, J. S., Kam, S. C., & Moon, K. H. (2016). 111 Relationship between Serum Testosterone and Nocturia in Men with Normal Prostate Size. The Journal of Sexual Medicine, 13(Supplement_1), S53–S53. https://doi.org/10.1016/j.jsxm.2016.02.117
  59. Lwin, A., Butcher, M., Holland, B., Herberts, M., Clemons, J., Baas, W., Fiuk, J., Delfino, K., Althof, S., Köhler, T., & McVary, K. T. (2016). 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database. The Journal of Sexual Medicine, 13(Supplement_1), S26–S26. https://doi.org/10.1016/j.jsxm.2016.02.057
  60. Rowland, D., Motofei, I., Popa, F., Constantin, V., Vasilache, A., Păunică, I., Bălălău, C., Păunică, G. P., Banu, P., & Păunică, S. (2016). The postfinasteride syndrome; an overview. Journal of Mind and Medical Sciences, 3(2), 99–107. https://scholar.valpo.edu/jmms/vol3/iss2/2/
  61. Ali, A. K., Heran, B. S., & Etminan, M. (2015). Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 35(7), 687–695. Portico. https://doi.org/10.1002/phar.1612
  62. Caruso, D., Abbiati, F., Giatti, S., Romano, S., Fusco, L., Cavaletti, G., & Melcangi, R. C. (2015). Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. The Journal of Steroid Biochemistry and Molecular Biology, 146, 74–79. https://doi.org/10.1016/j.jsbmb.2014.03.012
  63. Giatti, S., Foglio, B., Romano, S., Pesaresi, M., Panzica, G., Garcia-Segura, L. M., Caruso, D., & Melcangi, R. C. (2015). Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and Their Receptors in the Male Rat Brain. Neuroendocrinology, 103(6), 746–757. Portico. https://doi.org/10.1159/000442982
  64. Mirela, M., Ioana, P., Maria, P. G., & Mihnea, M. C. (2015). Finasteride Side Effects and Post-Finasteride Syndrome in Male Androgenic Alopecia. Journal of Mind and Medical Sciences, 2(2), 142–149. https://scholar.valpo.edu/jmms/vol2/iss2/6/
  65. Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. M., & Zitzmann, M. (2015). Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Reviews in Endocrine and Metabolic Disorders, 16(3), 177–198. https://doi.org/10.1007/s11154-015-9319-y
  66. Cecchin, E., De Mattia, E., Mazzon, G., Cauci, S., Trombetta, C., & Toffoli, G. (2014). A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation. The International Journal of Biological Markers, 29(4), 310–316. https://doi.org/10.5301/jbm.5000095
  67. Ganzer, C. A., Jacobs, A. R., & Iqbal, F. (2014). Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride. American Journal of Men’s Health, 9(3), 222–228. https://doi.org/10.1177/1557988314538445
  68. Irwig, M. S. (2014). Persistent Sexual and Nonsexual Adverse Effects of Finasteride in Younger Men. Sexual Medicine Reviews, 2(1), 24–35. https://doi.org/10.1002/smrj.19
  69. Di Loreto C., La Marra F., Mazzon G., Belgrano E., Trombetta C., Cauci S.: Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. PLoS One 9(6), e100237 (2014). doi:10.1371/journal.pone.0100237PONE-D-13-53954 
  70. Irwig, M. S. (2013). Decreased Alcohol Consumption Among Former Male Users of Finasteride with Persistent Sexual Side Effects: A Preliminary Report. Alcoholism: Clinical and Experimental Research, 37(11), 1823–1826. https://doi.org/10.1111/acer.12177
  71. Melcangi, R. C., Caruso, D., Abbiati, F., Giatti, S., Calabrese, D., Piazza, F., & Cavaletti, G. (2013). Neuroactive Steroid Levels are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology. The Journal of Sexual Medicine, 10(10), 2598–2603. https://doi.org/10.1111/jsm.12269
  72. Irwig, M. S. (2012). Depressive Symptoms and Suicidal Thoughts Among Former Users of Finasteride With Persistent Sexual Side Effects. The Journal of Clinical Psychiatry, 73(09), 1220–1223. https://doi.org/10.4088/jcp.12m07887
  73. Gur S., Kadowitz P.J., Hellstrom W.J.: Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf 12(1), 81-90 (2012). doi:10.1517/14740338.2013.742885
  74. Irwig, M. S. (2012). Persistent Sexual Side Effects of Finasteride: Could They be Permanent? The Journal of Sexual Medicine, 9(11), 2927–2932. https://doi.org/10.1111/j.1743-6109.2012.02846.x
  75. Zhang, M., Wu, W., Zhang, C., Wang, X., Gao, P., Lu, Y., & Shen, Z. (2012). Effects of Oral Finasteride on Erectile Function in a Rat Model. The Journal of Sexual Medicine, 9(5), 1328–1336. https://doi.org/10.1111/j.1743-6109.2012.02661.x
  76. Berthold, D., Lhermitte, B., Uffer, M., & Doerfler, A. (2011). Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia, 44, 836–837. https://doi.org/10.1111/j.1439-0272.2011.01214.x
  77. Chiba, K., Yamaguchi, K., Li, F., Ando, M., & Fujisawa, M. (2011). Finasteride-associated male infertility. Fertility and Sterility, 95(5), 1786.e9-1786.e11. https://doi.org/10.1016/j.fertnstert.2010.12.001
  78. Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M., & Hansen, M. L. (2011). Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients. The Journal of Sexual Medicine, 8(3), 872–884. https://doi.org/10.1111/j.1743-6109.2010.02157.x
  79. Tu, H. Y. V., & Zini, A. (2011). Finasteride-induced secondary infertility associated with sperm DNA damage. Fertility and Sterility, 95(6), 2125.e13-2125.e14. https://doi.org/10.1016/j.fertnstert.2010.12.061
  80. Moreno‐Fernandez, A., Mira Laguarda, J. M., Ruiz‐Hornillos, F. J., & Rubio Sotes, M. (2010). Urticarial rush due to finasteride. Allergy, 65(3), 405–406. Portico. https://doi.org/10.1111/j.1398-9995.2009.02165.x
  81. Römer, B., & Gass, P. (2010). Finasteride‐induced depression: new insights into possible pathomechanisms. Journal of Cosmetic Dermatology, 9(4), 331–332. Portico. https://doi.org/10.1111/j.1473-2165.2010.00533.x
  82. Farshi, S., Safar, F., & Mansouri, P. (2009). Finasteride-induced gynecomastia. Indian Journal of Dermatology, Venereology and Leprology, 75(3), 309. https://doi.org/10.4103/0378-6323.51273
  83. Rahimi-Ardabili, B., Pourandarjani, R., Habibollahi, P., & Mualeki, A. (2006). Finasteride induced depression: a prospective study. BMC Clinical Pharmacology, 6(1). https://doi.org/10.1186/1472-6904-6-7
  84. Michaela Duskova, Martin Hill, Miroslav Hanus, Michaela Matouskova & Luboslav Starka ‘Influence of the 5-alfa reductase inhibitor type 2 on circulating neuroactive steroids’, Endocrine Abstracts, 2008 https://www.endocrine-abstracts.org/ea/0016/ea0016p626
  85. Wessels H., Roy J, Bannow J, Grayhack J, Matsumoto A.M., Tenover L., Herlihy R., Fitch W., Labasky R., Auerbach S., Parra R., Rajfer J., Culbertson J., Lee M, Bach M.A., Waldstre-icher J., PLESS Study Group, Incidence and severity of sexual adverse experience in finasteride and placebo treated men with benign prostatic hyperplasia, Urology (2003); 61:579-84. https://onlinelibrary.wiley.com/doi/pdf/10.2164/jandrol.108.005025
  86. Altomare G., Capella G.L.: Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 29(10), 665-669 (2002). https://doi.org/10.1111/j.1346-8138.2002.tb00200.x
  87. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study.M C Uygur , A I Arik, U Altuğ, D Erol (1998)  https://doi.org/10.1016/s0039-128x(98)00005-1